Needham & Company LLC Raises CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $82.00

CRISPR Therapeutics (NASDAQ:CRSP) had its price target increased by analysts at Needham & Company LLC from $80.00 to $82.00 in a research note issued to investors on Friday, Marketbeat Ratings reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price target would suggest a potential upside of 54.51% from the company’s current price.

Other equities research analysts also recently issued reports about the company. Bank of America lowered their price target on CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating for the company in a report on Thursday, January 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Wednesday, January 21st. Wedbush cut their price target on shares of CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 5th. Royal Bank Of Canada boosted their price objective on shares of CRISPR Therapeutics from $42.00 to $50.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 11th. Finally, Robert W. Baird dropped their target price on CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. Eleven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $67.35.

CRISPR Therapeutics Stock Performance

CRSP opened at $53.07 on Friday. The firm’s fifty day moving average is $54.22 and its two-hundred day moving average is $57.36. The firm has a market cap of $5.06 billion, a PE ratio of -8.14 and a beta of 1.72. CRISPR Therapeutics has a twelve month low of $30.04 and a twelve month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.22). The firm had revenue of $0.86 million during the quarter, compared to analyst estimates of $4.72 million. CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.69%. CRISPR Therapeutics’s quarterly revenue was down 97.8% on a year-over-year basis. During the same period last year, the firm earned ($1.01) EPS. Equities analysts forecast that CRISPR Therapeutics will post -5.16 EPS for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 60,000 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $60.23, for a total transaction of $3,613,800.00. Following the transaction, the chief executive officer owned 134,201 shares of the company’s stock, valued at $8,082,926.23. The trade was a 30.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Royal Bank of Canada raised its position in CRISPR Therapeutics by 28.2% during the first quarter. Royal Bank of Canada now owns 142,696 shares of the company’s stock worth $4,856,000 after acquiring an additional 31,392 shares in the last quarter. AQR Capital Management LLC bought a new stake in shares of CRISPR Therapeutics in the 1st quarter valued at about $861,000. Woodline Partners LP lifted its stake in CRISPR Therapeutics by 34.3% in the 1st quarter. Woodline Partners LP now owns 136,483 shares of the company’s stock valued at $4,645,000 after purchasing an additional 34,883 shares during the last quarter. Janney Montgomery Scott LLC lifted its stake in CRISPR Therapeutics by 26.9% in the 2nd quarter. Janney Montgomery Scott LLC now owns 13,585 shares of the company’s stock valued at $661,000 after purchasing an additional 2,882 shares during the last quarter. Finally, KLP Kapitalforvaltning AS grew its holdings in CRISPR Therapeutics by 6.8% during the second quarter. KLP Kapitalforvaltning AS now owns 17,200 shares of the company’s stock worth $837,000 after purchasing an additional 1,100 shares during the period. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics News Summary

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Casgevy commercial momentum—management highlighted that Casgevy generated about $54M in Q4 and $116M for full‑year 2025, supporting the view that adoption for the company’s approved SCD/TDT therapy is expanding and producing meaningful sales. CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens
• Positive Sentiment: Analyst upgrade/price‑target lift—Needham raised its price target to $82 and maintained a Buy rating, signaling institutional conviction that shares have upside on continued commercial execution. CRSP Price Target Raised by Needham
• Neutral Sentiment: Official business update and results—CRISPR published its Q4 and full‑year 2025 results and a business update emphasizing pipeline progress and upcoming label expansion plans; this is informative for longer‑term thesis but contains limited near‑term financial guidance. CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Positive retail narrative—an upbeat Fool feature framed the company as a “blastoff‑ready” biotech pick for 2026, which can boost retail buying interest but is opinion‑driven. The Blastoff-Ready Biotech Stock You’ll Kick Yourself for Not Buying in 2026
• Neutral Sentiment: Short‑interest data appears anomalous—recent reports show short interest listed as 0 shares (likely a reporting/data issue), so short‑interest signaling is unclear and should be treated cautiously.
• Negative Sentiment: Quarterly miss and wider loss—CRSP reported Q4 EPS of ($1.37) versus consensus ($1.15) and revenue of $0.86M versus $4.72M expected; revenue fell sharply year‑over‑year, underscoring near‑term financial pressure and a negative margin/earnings backdrop. CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.